Drug Combo Shows Promise in Advanced Pancreatic Cancer
More than 70% of patients with pancreatic cancer derived a clinical benefit
when treated in a small, phase I trial with the combination of nanoparticle
albumin bound paclitaxel (Abraxane) and gemcitabine (Gemzar), investigators
reported here.
Run time 2.39 mins